1a.Objectives (from AD-416):
This collaborative research agreement seeks to explore the efficacy of Ankara Virus (APV) as a vector for expressing African Swine Fever Virus (ASFV) and Classical Swine Fever Virus (CSFV) proteins.
The specific objectives of this collaborative research project are:
1. Construct APV vectors expressing specific ASFV/CSFV genes.
2. Evaluate the protective effects of the mutated APV vectors.
1b.Approach (from AD-416):
1. USDA-ARS will identify and provide selected recombinant African Swine Fever Virus (ASFV) and Classical Swine Fever Virus (CSFV) genes which have known immunogenetic properties to the Univeristy of Wisconsin (UW). UW will manipulate the Ankara Virus (APV), introducing the recombinant ASFV/ CSFV genes, resulting in a mutated virus which, when replicated will express proteins encoded by the ASFV/ CSFV genes.
2. Resulting mutated viruses will be tested in swine in vivo by USDA-ARS. Challenge studies against and the presence of ASFV/CSFV-related signed and mortality rates will be assessed. Upon successful trails utilizing homologous virus, further studies will be conducted utilizing additional strains.
The purpose of this collaborative research is to assess the use of a well characterized expression vector, recombinant Ankara virus (RAV), to express and deliver African Swine Fever Virus (ASFV) proteins in swine. The University of Wisconsin provided ARS PIADC expertise in the development of RAV expressing foreign proteins. ARS PIADC provided The University of Wisconsin synthetic DNA encoding for several ASFV proteins historically characterized as putative protective immunogens that were used to developed two RAV that co-express several of those ASFV proteins. Expression of those ASFV proteins was detected in cell cultures infected with the RAV.
No technologies were transferred or publications prepared in FY 2013.